

Faculty disclosures

Prof. Sean Gaine has received honoraria for lectures and drug safety board activities from companies involved in PH including Actelion and United Therapeutics.

Prof. Robert Naeije has received honoraria or consultation fees as an IDMC member for trials sponsored by Actelion.

Prof. Andrew Peacock has received grants or research support from Actelion and Bayer, as well as honoraria or consultation fees from Actelion and Pfizer.

Dr. Michele D'Alto has served on advisory board and received travels fee from Actelion, GSK, MSD, Dompè, and Bayer.

Dr. Martin Keith Johnson has declared no conflict of interest.

Prof. Bouchra Lamia has declared no conflict of interest.

Prof. Dr. Irene Lang has been involved with the following companies: Actelion Pharmaceuticals Ltd., Astra-Zeneca Austria Ges.m.b.H., AOPOrphan Pharmaceuticals AG, Medtronic Austria Ges.m.b.H., Ferrer and United Therapeutics Corporation. In addition to being investigator in trials involving these companies, involvement includes consultancy service, research grants, and membership of scientific advisory boards.

Dr. Mareike Lankeit has declared no conflict of interest.

Prof. David Montani has declared no conflict of interest.

Dr. Michael Sproule has declared no conflict of interest.

Dr. Patrick Yerly has declared no conflict of interest.

Dr. Roberto Badagliacca has received fees for advisory boards and speech from Bayer, MSD, Dompè, Ferrer, GSK, and UT.